Background: The European Society for Medical Oncology (ESMO) recently released a magnitude of clinical benefit scale (ESMO-MCBS) for systemic therapies for solid cancers. Here, we evaluate contemporary randomized controlled trials (RCTs) against the proposed ESMO thresholds for meaningful clinical benefit.
Introduction
There is growing concern that many claimed advances in cancer therapy do not provide meaningful benefit to patients. Although novel therapies are often associated with modest efficacy, substantial toxicity, and high cost, there is pressure on regulatory authorities to reduce the bar for cancer drug approval [1, 2] . Use of surrogate endpoints and biased reporting of trial results are also common and exaggerate the extent to which new cancer therapies provide benefit to patients [3, 4] .
Therapies that offer true 'clinical benefit' should provide meaningful improvement in the quantity and/or quality of survival. The concept of 'value' (outcomes compared to cost) is increasingly recognized as an important consideration in both the interpretation of clinical trials and the delivery of cancer care: small incremental gains in therapeutic endpoints, especially those that are unproven surrogates for survival or its quality, provide minimal value. The high cost of many new cancer medicines presents a huge challenge to the delivery of affordable cancer care, and increasingly formal value mechanisms such as the UK National Institute for Health and Care Excellence (NICE) are being used.
In light of the growing tension between scientific advances and the extent to which they offer true benefit to patients, the European Society for Medical Oncology (ESMO) recently published a framework for evaluating the clinical benefit of new therapies [5] . The magnitude of clinical benefit scale (ESMO-MCBS) in the context of medicines for solid cancers offers policy-makers a framework to determine whether to adopt and/or fund new therapies. The primary objective of the current study is to determine the extent to which recent randomized controlled trials (RCTs) evaluating new therapies for breast cancer, nonsmall cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic cancer meet ESMO thresholds for clinically meaningful benefit. The secondary objective is to determine the proportion of RCTs that were designed to detect an effect size that could meet the proposed threshold for meaningful clinical benefit.
Methods
Identifying the study cohort Figure S1 , available at Annals of Oncology online).
Data abstraction and scoring
A data abstraction form was design to capture information on study design, results, and interpretation. Two authors (JDP and BA) abstracted data from the eligible studies, each contributing to one half of the cohort. Inter-rater agreement was evaluated by applying the data abstraction form to 10 randomly selected RCTs from the study cohort and 10 randomly selected studies cited in the ESMO-MCBS paper [5] . A third author (CMB) resolved any disagreement between the two authors.
Details regarding study design, methodology, endpoints, and conclusions were abstracted. Author conclusions were assigned a score from 1 to 7 based on a Likert scale developed by Ridker and Torres [6] , assigned based upon first reading the abstract conclusion: scores of 5-7 endorsed the experimental arm, scores of 1-3 endorsed the control arm, and a score of 4 indicated neutrality. A score of 6 or 7 was defined as 'strong author endorsement' of the new cancer therapy [2] . The 2014 journal impact factors (IFs) were obtained online from Thomson Reuters Journal Citation Reports; they were classified as low (IF < 5. ESMO-MCBS grades were applied to the results of each study that reported a statistically significant difference in favour of the experimental arm, using the published ESMO-MCBS forms [5] . If there was no statistically significant difference in the primary endpoint between the arms of the trial, but there was for a secondary endpoint or pre-specified subgroup analysis, then this was used to generate an ESMO-MCBS grade. As per the proposed ESMO framework, the grade was assigned based on the lower limit of the 95% confidence interval (CI) of the hazard ratio (HR) [5] ; we also assigned a separate grade for the reported or point estimate HR. Any references to toxicity or quality of life data were sought in order to modify the ESMO-MCBS accordingly. Only statistically significant changes in toxicity or QOL parameters were used to modify the grades. Meaningful clinical benefit of reported study results was defined as a grade of A or B for those trials of curative intent and 5 or 4 for those trials of palliative intent, as proposed in the ESMO-MCBS framework [5] . A second quality-control check of the data occurred after completion of grading whereby one author (JDP) rescored all trials with a statistically significant difference favouring the experimental arms (n ¼ 138).
To evaluate the proportion of RCTs that are designed to detect differences that would meet the ESMO-MCBS threshold, we assigned a grade for the targeted effect size, as described in the power calculation of each RCT. If only a targeted HR or an absolute gain was presented, without defining the expected outcome for the control arm, we determined the highest possible grade using the appropriate form of the ESMO-MCBS. An example of this type of calculation is provided in the Supplementary Appendix, available at Annals of Oncology online. Since very few RCTs describe expected toxicity and quality of life in their methods section, we considered grades of C (curative intent) or 1 and 2 (palliative intent) to represent studies powered to detect an effect size that would be unable meet ESMO-MCBS thresholds: with these grades, it would be impossible for the studies to meet meaningful clinical benefit, even with lowered toxicity or improved quality of life. The point estimate HR was used in scoring the design of trials, as the 95% CI were not reported in the statistical design section of published RCTs.
Statistical analysis
Data were collected in an Excel file designed for this study, and imported into IBM SPSS (Version 23.0 for Windows, Armonk, New York, 2015) for statistical analysis. Comparisons between study groups were made using the Pearson chi-squared test. Results were considered significant at P value < 0.05. No correction was made for multiple comparisons.
Results
The search strategy yielded 834 articles, of which 557 were excluded for the following reasons (supplementary Figure S1 , available at Annals of Oncology online): reports of secondary/subset analyses (n ¼ 283), nonanti-cancer therapy (n ¼ 183), phase I/ II trial (n ¼ 21), pooled data from multiple RCTs (n ¼ 30), other cancer site (n ¼ 17), animal studies (n ¼ 1), reports that were not clinical trials (n ¼ 12), studies with 2Â2 factorial design (n ¼ 8), and studies which evaluated route of drug delivery (n ¼ 2). Characteristics of the remaining 277 phase III RCTs that formed the study cohort are shown in Table 1 . Breast cancer trials were the most common (40%), followed by NSCLC (31%), CRC (22 %), and pancreatic cancer (6%). Median sample size was 532 (range 39-9779). Treatment intent was palliative in 70% of trials and most studies involved cytotoxic chemotherapy (71%); 83% of RCTs were funded by industry. The primary endpoint was overall survival in 35% of trials.
Inter-rater agreement was 95% between authors (JDP and BA) for extraction of all study variables extracted from the 10 RCTs sampled from our study cohort. In assigning the ESMO-MCBS grades, there was 100% agreement between the two abstractors. There was also 100% agreement for ESMO-MCBS grades between the two abstractors and the authors of the original ESMO-MCBS paper for a second set of 10 RCTs [5] . On detailed review of the cohort (n ¼ 138) by one author (JDP), 132 grades were not adjusted, 2 no longer met the threshold, and 4 did meet the threshold, resulting in excellent agreement: a j statistic of 0.896 (P < 0.0001).
The ESMO-MCBS framework was applied to the results of 138 RCTs (50% of total cohort) in which there was a statistically significant difference favouring the experimental arm. The results of 43 (31%) of these trials met ESMO-MCBS benefit threshold when using the lower limit of the 95% CI for the HR, as recommended in the scoring system [5] . Stratifying by treatment intent demonstrates that 61% (19/31) of curative-intent RCTs and 22% (24/107, P < 0.001) of palliative intent RCTs met ESMO-MCBS thresholds. There were no other trial-specific factors associated with meeting the ESMO-MCBS threshold for benefit (Table 2) . When we applied the ESMO-MCBS score to the point estimate of the HR of each RCT, the proportion of statistically positive RCTs meeting the threshold for clinical benefit decreased to 25% (35/138).
Among the 226 RCTs in which an ESMO-MCBS design score could be assigned, only 31% (70/226) were designed to detect an effect size that could meet the clinical benefit threshold. For trials with curative intent, 65% (41/63) were designed to detect or exclude treatment effects that could meet ESMO-MCBS thresholds, whereas only 18% (29/163, P < 0.001) of studies with palliative intent would do so.
In exploratory analyses, we evaluated the association between ESMO-MCBS threshold, strength of author conclusion, and journal impact factor. RCTs with results meeting the ESMO-MCBS benefit threshold were more likely to be strongly endorsed by authors [Likert score 6-7: 86% (37/43) versus 58% (52/95), P < 0.001] than RCTs with results below the threshold. We did not observe any association between meeting ESMO-MCBS threshold for benefit and journal impact factor: 47% (20/43) of RCTs meeting ESMO-MCBS threshold were published in high impact factor journals compared to 44% (42/95) of RCTs not meeting threshold for benefit (P ¼ 0.728).
Discussion
In the present study, we applied systematically the recently published ESMO-MCB scale to a cohort of contemporary RCTs in order to understand the extent to which new anti-cancer therapies provide meaningful benefit to patients. Our analysis indicates that: (i) only 31% (43/138) of RCTs with results that favor the experimental arm meet the threshold for meaningful benefit, representing only 15% of all published RCTs; (ii) RCTs of curative intent therapy are substantially more likely than palliative intent trials to meet the benefit threshold; and, (iii) only 31% (70/ 226) of all RCTs are designed to detect or exclude a difference between treatment arms that could meet ESMO-MCBS criteria for meaningful benefit.
Prospective data relating to the applicability of the ESMO-MCBS will take several years to accrue, but understanding the magnitude of clinical benefit in recent RCTs should help to provide insights for funding organizations, regulatory authorities, and health technology agencies with respect to the design and interpretation of future RCTs evaluating new cancer therapies. A recent study assessed the feasibility of applying the ESMO-MCBS score in daily practice at a tertiary referral centre, and found ease in day-to-day applicability of the framework, encouraging its use in routine clinical practice [7] .
The American Society of Clinical Oncology (ASCO) has also proposed a method for evaluating clinical value with a threshold for meaningful clinical benefit set originally as a relative improvement in median OS of 20% for pre-specified patient populations [8] . The initial ASCO framework was limited because it could only be applied to select trials with specific diseases and specific 
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settings; when applied to our cohort of RCTs, e.g. only 74/277 (27%) of trials were eligible for application of the first-iteration of ASCO scoring, as opposed to 100% of trials for which the ESMO-MCBS scoring could be applied. Kumar et al. [9] applied the original ASCO framework to clinical trials of new cancer therapies approved by the US Food and Drug Administration (FDA) between October 2015 and March 2016 and found that 25/47 (53%) and 9/47 (19%) of studies met thresholds for progression-free survival and overall survival, respectively. The ASCO Value Framework (ASCO-VF) was revised in 2015 [10] and 2016 [11] , and now allows a score to be assigned to novel cancer therapies to better conceptualize their degree of benefit to patients. The intent of the two frameworks differ: while the ESMO-MCBS was derived to 'frame the appropriate use of limited public and personal resources to deliver cost-effective and affordable cancer care' [5] , ASCO-VF was designed to 'assist in facilitating shared decision-making with patients about clinical benefits and costs' [10] . The ASCO-VF scores the 'net health benefit' (NHB) of an experimental regimen compared to the control arm, no threshold values exist, and the ASCO Statement indicates that the NHB of a therapy evaluated in one trial should not be compared to that of another therapy evaluated in a different trial [10, 11] . Conversely, the ESMO-MCBS, based on expert opinion, allows for threshold values in HR and absolute gains, as well as the use of the absolute gain in OS/PFS of the control arm in the scoring process; it is this latter feature that allows for the possibility of inter-trial comparisons.
The word 'significant' is used in clinical and scientific discourse as a truncated form of the term 'statistically significant'. There is growing emphasis in oncology to distinguish findings with 'statistical significance' from results that have 'clinical significance' and are, therefore, 'meaningful' to patients [12] . The true clinical benefit of a therapy is its ability to allow patients to live longer and/or live better [5] . Many novel cancer drugs, particularly targeted therapy, have substantial costs associated with their use, but the relationship between cost and benefit is meager at best [13] . In this contemporary cohort, it is striking that only 30% of RCTs in breast, nonsmall cell lung, colorectal, and pancreatic cancers published in the past 5 years meet the ESMO-MCBS threshold for meaningful clinical benefit. Because the framework was only applied to those trials showing a statistically significant difference in favour of the experimental arm, our results suggest that only 15% of all RCTs identify therapies with meaningful benefit to patients. Moreover, our data demonstrate that the majority of contemporary 'mega-trials' are designed to detect a very small effect size that in most cases would not be considered 'clinically significant'. It is likely that the design of contemporary RCTs is at least in part driven by 'thresholds' inherent in the regulatory approval of a novel therapy. In the United States, e.g. the FDA implemented their own 'thresholds' for the regulatory approval of a drug in 1962, with an emphasis on both safety and efficacy [14] ; despite this, substantial variation still exists with respect to FDA approval of novel therapies, particularly in cancer medicine [15] . Our findings have important implications for the design and implementation of future RCTs in oncology.
We have demonstrated previously that study design and author interpretation of 'benefit' has evolved over time [2, 3] . Among a cohort of 458 RCTs published between 1975 and 2009, we found that median sample size increased from 100 in the 1970-1980s, to 446 in the 1990s, to 722 in [2005] [2006] [2007] [2008] [2009] . Despite effect size remaining stable over time, authors of modern RCTs were substantially more likely to strongly endorse the experimental arm of the trial as the new standard of care.
Our findings are relevant to a wide variety of policymakers, particularly regulatory agencies. There has been a consistent reduction in the level of evidence required for cancer medicines to be given marketing authorizations. Our results show that that the policies being prosecuted by both the FDA and European Medicines Agency are at odds with delivering treatments that have meaningful clinical benefit, further reducing society's ability to make rational value judgments and manage healthcare budgets.
One of the early criticisms of the ESMO-MCBS framework has been its use of lower end 95% CI of the HR to assign a benefit score. Since the width of the CI depends on the number of 'events' in the trial, it will become narrower as trial data mature; a corollary is that small trials will qualify more easily for efficacy than large trials of identical efficacy. Our data demonstrate that while 31% of RCTs favoring the experimental arm will meet ESMO-MCBS threshold when using the lower 95% CI, this decreases to 25% when the best estimate of the HR is used. The current ESMO-MCBS scoring system might, therefore, be overly permissive.
Although the ESMO-MCBS proposed thresholds are arbitrary, they have been developed through rigorous evidenced-base processes and, thus, serve as critical benchmarks for investigators, clinicians, and policy-makers to consider the extent to which a cancer therapy confers meaningful benefit to patients. The proposed thresholds have 'face validity', and they are relevant where regulatory drug approval may be granted on the basis of a single clinical trial showing a statistically significant difference compared to standard therapy in an endpoint that may not measure survival or its quality. Indeed, we have shown that authors of RCTs meeting ESMO-MCBS benefit thresholds were more likely to strongly endorse the study, which is an encouraging finding; that said, 53% of authors strongly therapies that did not meet ESMO-MCBS thresholds. The reasons for this are likely multifactorial; previous work has demonstrated that authors of modern RCTs are increasingly likely to strongly endorse novel therapies with modest effect sizes [2] .
Our study has several limitations. First, data abstraction and scoring ascribed to both abstract and study conclusions rely on subtle interpretations of language. We attempted to minimize errors by testing inter-rater agreement and confirming any ambiguous language with a third abstractor. Second, we acknowledge that our secondary objective of applying the ESMO-MCBS to the statistical design of trials is beyond the scope of the scoring system's development and validation. Application of these scores to the design is limited by both incomplete information and a paucity of toxicity and QOL data (see Supplementary Appendix, available at Annals of Oncology online) which can influence whether a new treatment meets the threshold for benefit. To address this limitation, we considered scores of C, 1, or 2 as not meeting meaningful clinical benefit, since any additional toxicity or QOL data would not raise these scores to a level that meets the benefit thresholds. Similarly, many studies in our cohort failed to present toxicity or QOL data with appropriate test statistics (i.e. P values), rendering the data inapplicable to ESMO-MCBS. Third, despite being powered to detect a small benefit, large trials may still meet meaningful clinical benefit by detecting a larger effect size than anticipated. For this reason, we were cautious in the wording of our secondary objective by stating that the targeted effect size would fall below the ESMO-MCBS benefit thresholds.
The oncology community is in the midst of a critical policy debate on equitable delivery of affordable cancer care. The aging population, rapid technical innovations, and static or declining economies will lead to increasing stress and demands on the health systems, with little headroom for increased total healthcare expenditures; it is, therefore crucial that the oncology community delivers new cancer therapies with high value for patients and society, and that funding priority be given to treatments which lead to substantial benefit. Results from our study demonstrate that the majority of contemporary clinical trials fail to identify therapies with meaningful clinical benefit for patients. Furthermore, the ESMO-MCBS should also be considered by investigators, regulatory authorities, and research funding bodies in the design of future clinical trials, as well as by policy-makers and clinicians in the context of whether a new therapy should be approved and used in routine practice.
